Literature DB >> 18465242

It is possible to classify non-erosive reflux disease (NERD) patients into endoscopically normal groups and minimal change groups by subjective symptoms and responsiveness to rabeprazole -- a report from a study with Japanese patients.

Motoyasu Kusano1, Naohito Shirai, Kanako Yamaguchi, Michio Hongo, Tsutomu Chiba, Yoshikazu Kinoshita.   

Abstract

The hypothesis that non-erosive reflux disease (NERD) patients comprise various subgroups is gaining popularity. This study was conducted to investigate the possibility of categorizing NERD patients according to symptom types and response to acid-suppressive drug rabeprazole (RPZ) 10 mg/day. NERD patients were classified as grade N (endoscopically normal), M (minimal change), or erosive GERD, and answered a 51-item, yes-or-no questionnaire pre and post-treatment. Compared to erosive GERD, clear differences existed in pretreatment prevalence of symptoms and responsiveness to RPZ in grades N and M; the results suggested stomachaches (especially at night) were significant symptoms in grade N and dysmotility-like symptoms like bloated stomach were significant in grade M while gastroesophageal reflux symptoms were significant in erosive GERD. Clinical significance of classifying NERD was indicated from different symptoms and responsiveness to PPI.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18465242     DOI: 10.1007/s10620-008-0290-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  28 in total

1.  Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota.

Authors:  G R Locke; N J Talley; S L Fett; A R Zinsmeister; L J Melton
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

2.  Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis.

Authors:  C M Bate; J R Green; A T Axon; F E Murray; G Tildesley; C E Emmas; M D Taylor
Journal:  Aliment Pharmacol Ther       Date:  1997-08       Impact factor: 8.171

3.  Diagnosis of gastroesophageal reflux disease using a new questionnaire.

Authors:  Yasuyuki Shimoyama; Motoyasu Kusano; Sayaka Sugimoto; Osamu Kawamura; Masaki Maeda; Keiko Minashi; Shikou Kuribayashi; Tatsuya Higuchi; Hiroaki Zai; Kyoko Ino; Tsutomu Horikoshi; Fumitaka Moki; Tadashi Sugiyama; Munetoshi Toki; Tsuneo Ohwada; Masatomo Mori
Journal:  J Gastroenterol Hepatol       Date:  2005-04       Impact factor: 4.029

Review 4.  Minimal changes in reflux esophagitis: red ones and white ones.

Authors:  Michio Hongo
Journal:  J Gastroenterol       Date:  2006-02       Impact factor: 7.527

Review 5.  Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.

Authors:  B van Pinxteren; M E Numans; P A Bonis; J Lau
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

6.  Differences in clinical characteristics between patients with endoscopy-negative reflux disease and erosive esophagitis in Japan.

Authors:  Yasuhiro Fujiwara; Kazuhide Higuchi; Masatsugu Shiba; Kazuki Yamamori; Yoko Watanabe; Eiji Sasaki; Kazunari Tominaga; Toshio Watanabe; Nobuhide Oshitani; Tetsuo Arakawa
Journal:  Am J Gastroenterol       Date:  2005-04       Impact factor: 10.864

Review 7.  Functional gastroduodenal disorders.

Authors:  Jan Tack; Nicholas J Talley; Michael Camilleri; Gerald Holtmann; Pinjin Hu; Juan-R Malagelada; Vincenzo Stanghellini
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

Review 8.  Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease.

Authors:  Ronnie Fass
Journal:  Am J Gastroenterol       Date:  2003-03       Impact factor: 10.864

9.  Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice.

Authors:  T L Venables; R D Newland; A C Patel; J Hole; C Wilcock; M L Turbitt
Journal:  Scand J Gastroenterol       Date:  1997-10       Impact factor: 2.423

Review 10.  [Endoscopic findings of GERD].

Authors:  Yoshio Hoshihara
Journal:  Nihon Rinsho       Date:  2004-08
View more
  5 in total

1.  Roux-en-Y reconstruction is superior to billroth I reconstruction in reducing reflux esophagitis after distal gastrectomy: special relationship with the angle of his.

Authors:  Tsutomu Namikawa; Hiroyuki Kitagawa; Takehiro Okabayashi; Takeki Sugimoto; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  World J Surg       Date:  2010-05       Impact factor: 3.352

2.  More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive gastroesophageal reflux disease during maintenance proton pump inhibitor therapy.

Authors:  Motoyasu Kusano; Hiroko Hosaka; Osamu Kawamura; Akiyo Kawada; Shiko Kuribayashi; Yasuyuki Shimoyama; Hidetoshi Yasuoka; Masafumi Mizuide; Taku Tomizawa; Toshihiko Sagawa; Ken Sato; Masanobu Yamada
Journal:  J Gastroenterol       Date:  2014-06-12       Impact factor: 7.527

3.  Clinical significance of gastroesophageal reflux disease with minimal change: a multicenter prospective observational study.

Authors:  Takashi Joh; Kazuhide Higuchi; Katsuhiko Iwakiri; Takeshi Kamiya; Ken Haruma; Koji Nakada; Noriaki Manabe
Journal:  Sci Rep       Date:  2022-09-03       Impact factor: 4.996

4.  Correlation between symptomatic improvement and quality of life in patients with reflux and dyspeptic symptoms.

Authors:  Seiji Arihiro; Tomohiro Kato; Kyoko Ito; Masayuki Saruta; Toshiki Nikami; Takeshi Suzuki; Hisao Tajiri
Journal:  J Clin Biochem Nutr       Date:  2011-12-07       Impact factor: 3.114

5.  Association between dyspeptic symptoms and endoscopic findings based on the Kyoto classification of gastritis in Japanese male.

Authors:  Kouji Takahashi; Mitsushige Sugimoto; Yusuke Kawai; Mariko Hamada; Eri Iwata; Ryota Niikura; Naoyoshi Nagata; Masakatsu Fukuzawa; Takao Itoi; Tetsuo Ohtsubo; Takashi Kawai
Journal:  J Clin Biochem Nutr       Date:  2021-10-19       Impact factor: 3.114

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.